Drug intelligence / Profile preview

n-caffeoyltyramine

Development stage
Preclinical
Lead developer
eXoZymes
Modality
Small Molecules
01

Overview

N-Caffeoyltyramine is a naturally occurring small molecule classified as a hydroxycinnamic acid amide, specifically a phenylpropanoid amide. It consists of a caffeoyl group attached to a tyramine backbone and is found in various plants, including Lycium chinense (goji berry) and Solanum tuberosum (potato). N-Caffeoyltyramine exhibits notable antioxidant, anti-inflammatory, and arginase inhibitory properties. Mechanistically, it inhibits the production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10), cyclooxygenase 2 (COX-2), and prostaglandin E2 in LPS-stimulated macrophages. It also suppresses c-Jun N-terminal kinase phosphorylation. Additional studies indicate that it can inhibit epidermal growth factor receptor protein tyrosine kinase activity and activate caspase 3, suggesting potential anti-cancer effects. More recently, N-Caffeoyltyramine has been identified as an agonist of hepatocyte nuclear factor 4 alpha (HNF4α) with implications for metabolic diseases such as non-alcoholic fatty liver disease by promoting mitochondrial function and lipophagy[1][5][6].

Other names
n-cis-caffeoyltyramine
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HNF4A (Hepatocyte nuclear factor 4 alpha)EGFR (Epidermal growth factor receptor)ARG1 (Arginase 1)NOS1 (nNOS)

Beyond the preview

Go deeper on n-caffeoyltyramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on n-caffeoyltyramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call